

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

APPROVAL FOR MARKETING OF THE GROUP'S PRODUCT INSULIN DEGLUDEC INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors (the “Board”) of the Company is pleased to announce that the applications for marketing of Insulin Degludec Injection (specifications: 3ml: 300U (refilled pen-type); 3ml: 300U (disposable pen-type)) submitted by Zhuhai United Bio-Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, have been approved by China National Medical Products Administration with drug approval numbers S20260015 and S20260016 respectively.

Insulin degludec is a new-generation ultra-long-acting basal insulin analog indicated for the treatment of diabetes in adults, and can be used as monotherapy or in combination with oral antidiabetic drugs or prandial insulin to comprehensively address the needs of long-term glycemic management in clinical practice. With once-daily subcutaneous administration, it provides ultra-long and stable glycemic control, a favorable safety profile and great flexibility in dosing time. Currently, insulin degludec has been listed in the Category B in the National Medical Insurance Drug List (2025 Edition).

This approval marks another key technological breakthrough for the Company in the field of diabetes. Moving forward, the Company will continue to advance the research and development of new products, strengthen its competitiveness and innovation in the biopharmaceutical industry, and focus on chronic disease treatment by delivering higher-quality products and a robust pipeline to serve clinical practice and benefit patients, which is expected to generate greater value for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 9 March 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.